Edward Chouchani, PhD, principal investigator of the Chouchani Lab at Dana-Farber Cancer Institute, was one of 18 scientists named as finalists for the 2026 Blavatnik National Awards for Young ...

Longwood Construction Notice: Ongoing construction near our Longwood campus may affect traffic in the area. Check the latest access changes before you travel. If you are a journalist and have a ...

Mario Germano Giuliani and Lisa Giuliani have made an extraordinary gift of $27.8 million to support research in multiple myeloma, Dana-Farber Cancer Institute announced today. It is one of the ...

The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one ...

A large population-based study led by researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Mass General Brigham suggests that genetic testing added to routine newborn ...

Sturdy Health and Dana-Farber collaborate to bring world-class cancer care to local community Dana-Farber Cancer Institute and Sturdy Health today opened a new clinic in Attleboro, offering expanded ...

Investigators at Dana-Farber Cancer Institute have developed a platform for systematically discovering molecular glues that could become protein degradation drug candidates. The platform could help ...

Dana-Farber Cancer Institute investigators and collaborators at Mass General Brigham have created a single algorithm that simultaneously predicts the likelihood of 348 distinct diseases for a given ...

Today, Dana-Farber Cancer Institute announced its intent to file an application for a Determination of Need (DON) with the Massachusetts Department of Public Health (DPH) to reestablish a radiation ...

The U.S. Food and Drug Administration (FDA) has approved a new therapy regimen for patients with “double-positive” metastatic breast cancer based on results of the phase 3 PATINA study led by Otto ...

The U.S. Food and Drug Administration (FDA) has approved pembrolizumab, an immunotherapy, plus belzutifan, a HIF-2α inhibitor, as adjuvant treatment for adult patients with renal cell carcinoma with a ...

Dana-Farber Cancer Institute today announced that the Yawkey Foundation made a generous $50 million grant to support Dana-Farber's planned cancer hospital and the Future of Cancer Care Fund. The gift ...